CAR-T cells take on stubborn muscle disease in first human test

NCT ID NCT07086404

Recruiting now Disease control Sponsor: Daishi Tian Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new treatment called GC012F, which uses a patient's own immune cells (CAR-T cells) to target and attack the cause of idiopathic inflammatory myopathy, a group of rare muscle diseases. The study will enroll 12 adults whose disease has not responded to standard therapies. The main goal is to check safety, including side effects, and to see how long the modified cells last in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GC012F CAR-T cells
What this could lead to: If successful, this could point toward a new treatment option for people with hard-to-treat inflammatory muscle disease.
What could go wrong: This is a very early, small trial (12 people) focused on safety, not effectiveness. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHY (IIM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic inflammatory myopathy myositis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC INFLAMMATORY MYOPATHY (IIM)

Contacts and locations

Locations

Tongji Hospital of Tongji Medical Colledge, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.